NCT00152451

Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

An Open-label, Exploratory, Multicenter, Dose-escalation Study Examining the Efficacy, Safety and Tolerability of Ucb 44212 Used at Doses of 10 mg, 20 mg, 40 mg and 80 mg b.i.d. (Total Daily Dose of 20 to 160 mg) in Adult Subjects (18-65 Years) With Refractory Epilepsy Suffering From Partial Onset Seizures (Whether or Not Secondarily Generalized) and Treated With 1, 2 or 3 Approved Antiepileptic Drugs

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: UCB S.A. - Pharma Sector · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.

Conditions

• Epilepsy, Partial

Interventions

Type	Name	Description
DRUG	Seletracetam (ucb 44212)	* Pharmaceutical form: oral capsules * Concentration: 10 and 50 mg * Route of administration: oral administration

Timeline

• Start date: 2005-05-19
• Primary completion: 2006-05-03
• Completion: 2006-05-03
• First posted: 2005-09-09
• Last updated: 2024-03-29
• Results posted: 2024-03-29

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study